RE: VRCI undervalued pharma stock by far on FTSE. Target: 20p for me.27 Mar 2025 13:59
For context, VRCI has much higher revenues than AGL (Angle), considerably lower costs (VRCI around break even, AGL £12-18m LOSS per annum) and the market cap is £5m for VRCI vs £30m for AGL.
This is due a considerable re-rate from here.